

Physician awareness of diagnostic and nondrug therapeutic costs: A systematic review

G. Michael Allan

University of Alberta and Institute of Health Economics

Joel Lexchin

York University and University Health Network

Objectives: The aim of this study was to investigate doctors' knowledge of the relative and absolute costs of diagnostic tests, medical consumables (e.g., syringes or intravenous tubing), and healthcare visits as well as to determine factors influencing awareness.

Methods: For this systematic review, we searched the Cochrane Library, EconoLit, EMBASE, and MEDLINE; reviewed reference lists; and had contact with authors. Studies were included if either doctors or trainees were surveyed, there were >10 survey respondents, costs of diagnostic or therapeutic items were estimated, results were expressed quantitatively, and a clear description was provided of how authors defined Accurate Estimates and determined True Cost. Two authors reviewed each article for eligibility and extracted data independently. Cost accuracy outcomes were summarized, but data were not combined due to extensive heterogeneity.

Results: Fourteen articles were included in the final analysis. Cost accuracy was low; 33 percent of estimates were within 20 percent or 25 percent of true cost and 50 percent were within 50 percent or in the 50–200 percent range of the true cost. Country, year of study, level of training, and specialty did not impact accuracy. The cost of items appears to have no impact on the accuracy (Fisher's exact test, $p = .41$) or pattern of estimation (binomial test, $p = .92$).

Conclusions: Doctors have a limited understanding of diagnostic and nondrug therapeutic costs, and we could not identify anything that impacts understanding of these costs. More focus is required in the education of physicians about costs and the access to cost information.

Keywords: Healthcare costs, Physician awareness, Investigations, Medical care, Systematic review

High costs are a major concern in almost all aspects of health care. Although pharmaceutical expenditures are the fastest growing expense, other costs including those of diagnostic procedures, equipment, imaging, investigations, laboratory tests, or visits to hospital (collectively here termed "diagnostic and therapeutic items" or D&T items) account for a large share of healthcare spending. Many of these costs are in-

curred in the hospital setting. Hospitals are the largest overall cost in health care in most of the Organization for Economic Cooperation and Development (OECD) countries, ranging from 27.1 percent in Poland to 48.4 percent in Japan (28). Whereas some D&T items, such as a single blood test, are inexpensive in isolation, the volume of these services can increase costs to significant levels, and many are tied in with the cost of personnel, which is the single largest expense in hospitals.

Although rarely available as a distinct cost, in one instance investigational services constituted almost 30 percent of expenditures for Australia's Medicare Services (13).

The authors acknowledge Ben Vandermeer for his statistical input and analysis. This study was funded by a \$5,000 grant from the Institute of Health Economics. The authors do not have any financial interests, relationships, or affiliations relevant to the subject matter of this manuscript.

Several studies have shown that test ordering is frequently excessive in most clinical environments, including primary care (24), emergency departments (37), preoperative assessment (23;27), hospitals (6), and specialized wards or clinics such as renal (19) or intensive care units (20). Furthermore, these tests generally have little impact on patient care (20;23;27) and in some cases may be harmful (8). Other studies have shown that cost increases of 60 percent over a variety of hospital and physician services do not improve patient outcomes but occasionally worsen them (17;18). If physicians were to reduce the use of unnecessary medical services, they could control costs without negatively impacting patient care. Physicians could also reduce costs by autonomously choosing the least costly diagnostic test, imaging technique, or investigation in cases where they have a choice and there are no significant differences in safety and effectiveness. Doctors must also consider costs to their patients, as approximately half of OECD countries require some form of direct payment for hospital services, either as co-payments or deductibles, from patients (15).

If physicians are going to take costs into consideration, they need to be cognizant of both the absolute cost of D&T items and the relative differences between prices, for example between the cost of a biochemistry panel including or excluding liver enzymes. However, in most places, this type of cost information is not easily available for doctors. To determine whether it is necessary to enhance both physicians' education about prices and the availability of that information, we undertook a systematic review to determine physicians' level of awareness of the cost of D&T items.

METHODS

The methods of this systematic review overlap those of the related systematic review of physician awareness of drug costs (3). Templates for the systematic review of survey studies are not well established but QUOROM (26) (normally reserved for systematic reviews of randomized controlled trials) is a good guide for most systematic reviews and was used here wherever possible.

Search

We searched the Cochrane Library (from 1966), EconLit (from 1969), EMBASE (from 1974), and MEDLINE (from 1950) up to May 31, 2005, using the search terms physician, doctor, medical student, house staff, intern or resident; medicine, medications, drug therapeutic, test, investigation or diagnostic test; cost or price; and knowledge, awareness, or understanding. (The results of the analysis of knowledge of drug costs are reported elsewhere (3).) The titles and abstracts, where available, were independently screened by both authors and if either investigator thought that the article would be potentially eligible a complete copy was obtained. To identify additional studies, the reference list of any potentially eligible article was searched and authors with two

or more publications in the area or who had published in the 10 years preceding the start of our review were contacted.

Eligibility

Articles were included if either doctors, trainees (interns or residents), or medical students were surveyed; there were more than ten survey respondents; costs of D&T items were estimated; results were expressed quantitatively; there was a clear description of how authors defined Accurate Estimates; and there was a clear description of how the True Cost was determined. Because costs are variable and complex, we believed it was only reasonable for doctors to have knowledge of the total costs of the D&T item, whether that cost was borne partially or completely by the patient and/or the insurer (private or government), in their local practice environment. Therefore, "True cost" was operationally defined as the actual cost the study authors verified from one or more locally relevant reliable sources for each D&T item in their study. The definition of "Accurate Estimates" was taken from the authors and typically fell within a defined "accuracy range" (e.g., ± 25 percent) around the true cost. Articles were excluded if they were not published in English or if participants were asked to estimate costs within ranges or cost increments only (for example "please estimate which \$20 cost category/range is most appropriate for drug A"). Both authors independently assessed each potential article for eligibility. Differences in decisions about inclusion and exclusion were resolved through consensus.

Data Extraction

From each eligible article, both authors independently extracted a range of data including information about the types of items surveyed, the location of the study, and the demographics of the respondents. Where data were not reported in a way that allowed extraction in one of our categories, we attempted to calculate the information from available data (e.g., number of respondents calculated from the number of surveys distributed multiplied by the response rate). Comparisons within studies, such as differences between medical student and resident accuracy, were extracted when available. Authors were contacted for further data where necessary. After each investigator independently extracted the above information, the results were compared and differences resolved by consensus.

Data Analysis

The studies were too diverse to combine meta-analytically (different therapies, different cost estimation procedures, different groups of physicians). Mean accuracy (expressed as the percent of physicians who correctly estimated D&T costs) for each study was calculated by averaging the accuracy from each participant group or D&T item estimated with weighting for the number of estimation attempts. For example, if accuracy was 30 percent for D&T A ($n = 100$) and 50 percent

for D&T B ($n = 80$), the average accuracy would be 39 percent $((0.30 \times 100) + (0.5 \times 80))/180$. We calculated nonparametric summaries (median and ranges [minimum–maximum]) for the following outcomes: average cost accuracy (within defined percent margins of error), average percent of estimates over and under true cost or the margins of error (as defined by the original authors) around the true costs, and average percent error $(\text{estimate} - \text{true cost}) / \text{true cost}$.

Percent error is the statistic used to demonstrate the degree of estimation error. To be reliable, each estimate error (the amount above or below the true cost) must be converted to an absolute value. If not, high estimates will be positive numbers and low estimates will be negative numbers, and when summed will partially cancel each other giving a lower value and a false impression of accuracy. For example, if the true cost of a D&T item is \$100 and two doctors estimate \$50 and \$150, respectively, the correct percent error would be 50 percent. However, if absolute values were not used, the percent error of the high estimation error would be 50 percent and the low would be -50 percent. This would make the combined percent error 0 percent, indicating no error in estimation and yield a false representation of perfect accuracy.

Additionally, a priori defined subgroups, such as year of publication (divided by median year of publication of studies), location of study, training level of participants, and specialty, were examined to determine whether these variables influenced the accuracy of the cost estimation. We also examined the influence of study quality on estimation accuracy by separating studies with a similar accuracy range into those of high and moderate–low quality. For this analysis, we used weaknesses of response rate (≤ 50 percent or unclear), sampling method (convenience or unclear), and survey distribution (unclear) as markers of quality. Although there is no defined adequate response rate, low response rates can bias surveys (5;38), and we believed 50 percent was generous. Non-probability sampling, such as convenience sampling, can bias studies because the sample is not representative of the population. Different modes of questionnaire administration have different inherent biases, and although there is no clearly superior method (11), we believed the information was important in reviewing surveys. High quality studies had none of these weaknesses, moderate quality studies had one weakness, and low quality had two or more weaknesses. The use of these measures to assess quality has face validity as it was based on our understanding of the places where the greatest biases can occur in survey studies.

We also performed two sensitivity analyses. To minimize the heterogeneity inherent in comparing studies with multiple different services, we compared the average cost accuracies for specific D&T items among four or more studies. When data could not be combined and nonparametric statistics such as medians and ranges must be used, there is a concern that larger studies are weighted equally with smaller ones. To de-

termine the potential influence of “weighting,” we performed sensitivity analyses where the median nonparametric statistic was selected based on the number of services in each study, the number of physicians in each study, or the total number of estimates in each study.

Lastly, where data could be extracted from studies on the true cost of an individual D&T item, we examined the influence of the true cost in two dimensions—are doctors better able to estimate the cost of inexpensive items versus expensive ones (accuracy), and do doctors underestimate the cost of expensive items and overestimate the cost of inexpensive ones (estimation pattern). We undertook this analysis because we have previously shown that the true cost has the largest influence on the accuracy and estimation pattern for drugs (3). To separate D&T items into high and low cost groups, in each study we looked at the cost of the items in the study to see if there were distinct cost groups that might serve to delineate high from low cost items (For example, if a study had twenty-five items with ten items under \$5 and the remaining fifteen items over \$40, we would separate the groups that way). If there was no distinct high and low cost group, we used the median D&T item cost for best high/low cost dividing point for that study.

Ethics approval was not required as the research involved publicly available material.

RESULTS

Literature Search and Selection

A study flow diagram is provided in Figure 1. Eleven authors were contacted to identify possible studies, and six responded to yield two previously unidentified studies, neither of these studies was ultimately included. From a total of 2,954, fourteen studies were included in the systematic review (1;2;4;12;14;16;21;25;29;31;33;34;36;39).

Study Characteristics

The main characteristics and methodological aspects of each study are provided in Table 1. Studies were conducted from 1976 to 2004 in five countries with the United States ($n = 5$), United Kingdom ($n = 4$), and Canada ($n = 3$) predominating. Seven studies included licensed physicians only, one involved house staff only, and five included a mixture of participants (licensed physicians, house staff, and medical students). Four studies involved general practitioners (GP) alone, five specific specialists groups, three a mix, and two were unclear as to the specialty of the doctors.

Hospital-based studies in Canada, Denmark, Italy, United Kingdom, and United States defined true costs as acquisition costs (12;34), billing costs (14;36;39), costs obtained through surveys (21), and wholesale costs paid by the hospital (4;16;25). Three outpatient studies used surveys (29;31;33) and two used a combination of billing and acquisition costs (1;2).




Figure 1. Study identification and selection.

Studies looked at physicians' knowledge of three broad categories of D&T items—investigations (1;2;14;21;29;31;33;36;39), medical supplies (4;12;14;16;25;29;34), and medical care (1;2;14;39) (Supplementary Table S1, which can be viewed online at http://www.journals.cambridge.org/jid_thc). The number of different D&T items estimated per study ranged from one (cost of mammography) to forty.

Study Quality

The method of survey distribution was unclear in four studies (14;16;29;39), and sampling was convenience or unclear in eight studies (4;14;16;21;25;29;31;34). The response rates were ≤ 50 percent or unknown in four stud-

ies (2;14;29;39). Only four (29 percent) of fourteen studies (1;12;33;36) did not have any of these three weaknesses (Supplementary Table S2, which can be viewed online at http://www.journals.cambridge.org/jid_thc). In addition, of nine studies attempting to quantify the degree of estimation error (for example percent error) (1;2;4;16;21;25;31;33;34), six used average estimations without regard for signage (i.e., averaging overestimates with underestimates) or inadequately described the calculation (4;16;25;31;33;34). In total, eleven (79 percent) of the fourteen studies had one or more of these four weaknesses, and only three trials (1;12;36) were without significant weaknesses. There was also a large variation in study design: four methods were used to determine true costs, and reasonable accuracy was defined nine different ways.

Table 1. Study Characteristics

First author	Publication year	Country	Participants' training level	Specialty	Number responding (response rate as%)	Sample selection	Mode of survey administration	True cost determined from
Allan 1 (1)	2002	Canada	HS	GP	82 (85)	Entire	Meeting/mail	Billing/ acquisition
Allan 2 (2)	2004	Canada	Lic	GP	283 (47.2)	Random	Mail	Billing/ acquisition
Bailey (4)	1993	UK	Lic/HS	Anesthesia	40 (100)	Convenience	Face to face	Wholesale
Conti (12)	1998	Italy	Lic/HS	Mix	60 (100)	Random	Face to face	Acquisition
Dresnick (14)	1979	USA	Lic/HS/MS	Mix	427 (ns)	Unclear	Unclear	Billing
Fairbass (16)	1988	UK	Lic	Anesthesia	20 (100)	Unclear	Unclear	Wholesale
Innes (21)	2000	Canada	Lic	Emergency	75 (100)	Convenience	Face to face	Survey
Mills (25)	1993	UK	Lic	Anesthesia	20 (100)	Convenience	Face to face	Wholesale
Perrine (29)	1982	USA	Lic/HS	GP	58 (48*)	Unclear	Unclear	Survey
Ringenberg (31)	1988	USA	HS	GP	65 (72)	Convenience	Meeting	Survey
Saunders (33)	1994	USA	Lic	Mix	506 (57)	Random	Mail	Survey
Schlunzen (34)	1999	Denmark	Lic	Anesthesia	47 (92.2)	Unclear	Hospital mail	Acquisition
Skipper (36)	1976	USA	Lic/HS/MS	ns	61 (68)	Random	Hospital mail	Billing
Wynick (39)	1985	UK	Lic	ns	82 (48)	Entire	Unclear	Billing

*Exact number surveyed unclear ("approximately 120") so response rate approximate.

HS, house staff; Lic, licensed physicians; MS, medical students; GP, general practitioner or family physician; Mix, mixture of specialized physicians; ns, not specified.

Table 2. Estimation Accuracy Summaries

Definition	No. of studies	Median% (range)	References
All medical care			
Within 75/80–120/125%	7	33 (13–41)	(1;2;12;14;21;29;36)
Within 50–150/200%	8	50 (38–68)	(1;2;4;16;25;31;31;34;39)
Overestimation ^a	5	34 (27–46)	(1;2;21;36;39)
Underestimation ^a	5	48 (23–59)	(1;2;21;36;39)
Percent error ^b	3	54 (47–92)	(1;2;21)
Investigation			
Within 75/80–120/125%	6	33 (25–40)	(1;2;14;21;29;36)
Within 50–150/200%	4	54 (49–68)	(1;2;31;39)
Overestimation ^a	5	34 (4–41)	(1;2;21;36;39)
Underestimation ^a	5	48 (38–64)	(1;2;21;36;39)
Percent error ^b	3	53 (48–92)	(1;2;21)
Medical supplies			
Within 50–150/200%	5	44 (38–60)	(4;16;25;34;39)
Medical care visit			
Within 75/80–120/125%	3	50 (41–53)	(1;2;14)
Within 50–150/200%	3	66 (60–82)	(1;2;39)
Overestimation ^a	3	74 (12–80)	(1;2;39)
Underestimation ^a	3	20 (6–26)	(1;2;39)

^aPercent of estimates above or below the accuracy ranges around the true costs. Ranges were true cost (1;2), the range of true (21), 75–125 (36), and 50–200 (39).

^bEstimate – True Cost / True Cost.

Estimation Accuracy

Table 2 summarizes cost accuracy outcomes. Using the more restrictive criterion of accuracy (75/80–120/125 percent), accuracy for all D&T items was 33 percent; increasing to 50 percent with a more liberal criterion of 50–150/200 percent. Investigations and medical care visits showed the same pattern of better percent accuracy with more liberal crite-

ria. Except for the cost of a medical care visit, average cost accuracy was not more than 54 percent whatever the criterion used. Underestimation tended to be greater than overestimation, with the exception of medical care visits, and percent error was in the range of 50 percent, but it could only be measured for three studies that dealt with investigations.

Table 3. Between-Study Comparisons in Cost Accuracy

	No. of studies	Median% (range)	References
75/80–120/125%			
Country			
Canada	3	30 (27–34)	(1;2;21)
USA	3	35 (33–41)	(14;29;36)
Year			
≤1990	3	35 (33–41)	(14;29;36)
≥1991	4	29 (13–34)	(1;2;12;21)
Physician			
Generalist	3	30 (27–33)	(1;2;29)
Specialist	3	34 (13–41)	(12;14;21)
Quality			
High	3	27(13–35)	(1;12;36)
Moderate–low	4	33 (30–41)	(2;14;21;29)
50%–150/200%			
Country			
UK	4	47 (44–60)	(4;16;25;39)
Canada, USA, Denmark	4	53 (38–68)	(1;2;31;34)
Year			
≤1990	3	48 (44–68)	(16;31;39)
≥1991	5	51 (38–60)	(1;2;4;25;34)
Physician			
Generalist	3	56 (51–68)	(1;2;31)
Specialist	4	46 (38–60)	(4;16;25;34)
Training			
Licensed	5	48 (44–60)	(2;16;25;34;39)
House staff	3	51 (47–68)	(1;4;31)

In the sensitivity analysis of estimation accuracy (for studies using ± 20 percent or ± 25 percent), the number of therapies, the number of physicians, and the number of estimations for each study did not change the median accuracy more than 1 percent. Estimation variability between studies is compared by removing some of the heterogeneity and focusing on individual D&T items common to four or more studies (Supplementary Figure S1, which can be viewed online at http://www.journals.cambridge.org/jid_thc).

Subgroup Analysis

Table 3 presents nonparametric summaries for subgroups using the most commonly used margin of error (75/80–120/125 percent). The median percent accuracy clustered around 30 percent and was not significantly affected by the country where the study took place (Canada versus the United States), the median year of publication (≤ 1990 versus ≥ 1991), or the specialty of the respondents (general practitioners versus specialists). The studies where doctors worked in a mix of community and hospital settings all involved general practitioners, whereas the studies where doctors worked primarily in hospital settings all involved specialists. Therefore, the results when different types of work settings are compared (mix of community and hospital versus primarily hospital) are identical to those when general practitioners and specialists are compared. Results using a wider margin of error (50–150/200 percent) were somewhat better as would be expected but once again were not different within subgroups,

including the additional subgroup of training level (licensed doctor versus house staff).

There were insufficient data to present median accuracies and ranges for the low and moderate quality groups separately; therefore, we combined data for these two. Median percent accuracy was slightly worse (27 percent; range, 13–35 percent) for high quality studies compared with those of moderate–low quality (33 percent; range, 30–41 percent).

Four studies (1;2;21;39) provided enough data (true cost and the percent of high/low estimations for each D&T item) to examine whether the true cost of each item affected the estimation pattern, that is, did doctors consistently underestimate the cost of high priced items and overestimate the price of low priced ones. Analysis of the 100 D&T items in these studies showed this was not the case (binomial test, 51/100, $p = .92$).

Seven studies (1;2;14;21;29;31;39) provided enough data (true cost and estimation accuracy for each D&T item) to examine whether doctors are better able to estimate the true cost of expensive items, compared with inexpensive ones. Our results showed that expensive items are not estimated more accurately than inexpensive items. Compared with the mean estimation accuracies for these seven studies, thirty-six of seventy-nine (46 percent) inexpensive D&T items had a higher estimation accuracy, whereas thirty-six of sixty-seven (54 percent) of expensive D&T items had a higher estimation accuracy (46 percent versus 54 percent, Fisher's exact test, $p = .41$).

DISCUSSION

Physician awareness of D&T medical care cost items is poor. Only 33 percent of estimates were within ± 20 percent or ± 25 percent of the true cost and 50 percent were within ± 50 percent or in the 50–200 percent range of the true cost. Country, year of study, level of training, and specialty seem to have limited impact over both primary accuracy ranges. For example, within the ± 50 percent or 50–200 percent accuracy range, generalists seem to be more accurate than specialists (56 percent versus 46 percent respectively) but at the ± 20 percent or ± 25 percent accuracy ranges generalists are less accurate than specialists (30 percent versus 34 percent, respectively). Comparing accuracy over different D&T items, the median accuracy (within ± 50 percent or 50–200 percent) improves approximately 10 percent from medical supplies (44 percent) to investigations (54 percent) to medical care visits (66 percent). However, the range of accuracies within these groups overlap, with an accuracy for medical supplies (60 percent) in one study (25) the same as that for the medical care visits (60 percent) in another (1). Study quality may have impacted the results as mid and low quality studies have higher estimation accuracy than high quality studies, 33 percent (range, 30–41) versus 27 percent (range, 13–35), respectively. Unfortunately, there are inadequate numbers of studies in the different quality subgroups to allow for further

comparisons, so it remains uncertain how much lower quality trials may bias results favorably.

Compared with the corresponding study on drugs (3), estimation accuracy in this study was slightly better (33 percent for D&T versus 31 percent for drugs) and the median error was considerably less (54 percent for D&T versus 243 percent for drugs). This finding suggests that, although doctors have difficulty getting within a particular margin of error (e.g., ± 20 percent or ± 25 percent), they have a better sense of the approximate cost of D&T items compared with drugs. Supplementary Figure S1 (which can be viewed online at http://www.journals.cambridge.org/jid_thc) shows that variability between studies persists even when focusing on the same tests. In the study on the accuracy of the estimation of the cost of drugs (3), the true cost of the drugs explained a good part of this variability. However, in this study, there was no consistent pattern. In Innes et al. (21), the true cost of a urine culture was almost twice as much as in some other studies, and the accuracy of doctors in Innes was higher than other studies in which doctors also estimated urine culture costs. In Perrine (29), the true cost of urinalysis was only one third the cost in some other studies, but the accuracy of doctors in Perrine was still higher than other studies in which doctors estimated urinalysis costs.

Looking over all studies with available data, the true cost of D&T items did not influence estimation accuracy or the pattern of estimation (whether doctors would guess high or low), whereas for drugs, the true cost appears to be the strongest predictor of estimation accuracy and estimation pattern (3). As the true cost of items increases, the acceptable percent margin of error makes the absolute dollar margin of error quite large. For example, in a study using ± 25 percent as the acceptable margin of error, a doctor would have to be within \$0.25 (\$0.75 to \$1.25) of an item costing \$1 compared with \$25 for an item costing \$100. Therefore, it is surprising that accuracy was not significantly better with higher cost items.

Other studies that have focused on pharmaceuticals have shown that doctors do care about healthcare costs regardless of whether the patient or a third party pays (10;30;35). Furthermore, when cost information is provided or if doctors receive feedback/education about costs (7;9;22;32), they modify their behaviour and reduce costs. Clearly, more could be done to help doctors improve their ordering and reduce costs. We suggest providing cost information with lab and diagnostic imaging requisitions. Additionally, physicians should also receive feedback and education on the cost of individual items that they have ordered along with how they compare with their peers and suggestions for modifying their practices.

Limitations

Although our review could potentially have been biased by the exclusion of non-English studies, no studies in other languages were identified by our search strategy. Only three of

the fourteen studies are from 2000 and later, so it is possible that the findings of this review do not reflect physicians' current awareness of D&T items. However, as physician awareness did not appear to change over the 30-year span of these studies, it is highly likely that it remains poor. Finally, all but two of the fourteen studies came from Canada, the United Kingdom, or the United States, and results may be different in other countries.

CONTACT INFORMATION

G. Michael Allan, MD (michael.allan@ualberta.ca), Assistant Professor, Department of Family Medicine, University of Alberta, 901 College Plaza, Edmonton, Alberta T6G 2C8, Canada; Research Fellow, Institute of Health Economics, #1200, 10405 Jasper Avenue, Edmonton, Alberta T5J 3N4, Canada

Joel Lexchin, MSc, MD (jlexchin@yorku.ca), Professor, School of Health Policy and Management, York University, 4700 Keele Street, Toronto, Ontario M3J 1P3, Canada; Active Staff, Department of Emergency Medicine, University Health Network, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada

REFERENCES

- Allan GM, Innes G. Family practice residents' awareness of medical care costs in British Columbia. *Fam Med*. 2002;34:106-111.
- Allan GM, Innes G. Do family physicians know the costs of medical care? *Can Fam Physician*. 2004;50:263-270.
- Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: A systematic review. *PLoS Med*. 2007;4:e283.
- Bailey CR, Ruggier R, Cashman JN. Anaesthesia: Cheap at twice the price? Staff awareness, cost comparisons and recommendations for economic savings. *Anaesthesia*. 1993;48:906-909.
- Barclay S, Todd C, Finlay I, Grande G, Wyatt P. Not another questionnaire! Maximizing the response rate, predicting non-response and assessing non-response bias in postal questionnaire studies of GPs. *Fam Pract*. 2002;19:105-111.
- Bareford D, Hayling A. Inappropriate use of laboratory services: Long term combined approach to modify request patterns. *BMJ*. 1990;301:1305-1307.
- Beilby JJ, Silagy CA. Trials of providing costing information to GPs: A systematic review. *Med J Aust*. 1997;167:89-92.
- Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. *N Engl J Med*. 1993;328:1237-1243.
- Blackstone ME, Miller RS, Hodgson AJ, et al. Lowering hospital charges in the trauma intensive care unit while maintaining quality of care by increasing resident and attending physician awareness. *J Trauma*. 1995;39:1041-1044.
- Boiver PA, Martin DP, Perneger TV. Cost-consciousness among Swiss doctors: Cross-sectional survey. *BMC Health Serv Res*. 2005;5:72.
- Bowling A. Mode of questionnaire administration can have serious effects on data quality. *J Public Health*. 2005;27:281-291.

12. Conti G, Dell'Utri D, Pelaia P, et al. Do we know the costs of what we prescribe? A study on awareness of the cost of drugs and devices among ICU staff. *Intensive Care Med.* 1998;24:1194-1198.
13. Conyers RAJ. Modifying the use of pathology services. *Med J Aust.* 1999;170:8-9.
14. Dresnick SJ, Roth WI, Linn BS, Pratt TC, Blum A. The physician's role in the cost-containment problem. *JAMA.* 1979;241:1606-1609.
15. Esmail N, Walker M. *How good is Canadian health care? An international comparison of health care systems.* Vancouver: Fraser Institute; 2002.
16. Fairbass MJ, Chaffe AG. Staff awareness of cost of anaesthetic drugs, fluids, and disposables. *BMJ.* 1988;296:1040.
17. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending. Part 1: Health the content, quality and accessibility of care. *Ann Intern Med.* 2003;138:273-287.
18. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending. Part 2: Health outcomes and satisfaction with care. *Ann Intern Med.* 2003;138:288-298.
19. Gardner MD, Henderson AR. Test request patterns for clinical chemistry in a British and a Canadian renal dialysis unit. *Clin Chem.* 1983;29:1546-1548.
20. Graat ME, Kröner A, Spronk PE, et al. Elimination of daily routine chest radiographs in a mixed medical-surgical intensive care unit. *Intensive Care Med.* 2007;33:639-644.
21. Innes G, Grafstein E, McGrogan J. Do emergency physicians know the costs of medical care? *CJEM.* 2000;2:95-102.
22. Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman AD. Audit and feedback: Effects on professional practice and health care outcomes. *Cochrane Database Syst Rev.* 2006;2:CD000259.
23. Johnson RK, Mortimer AJ. Routine pre-operative blood testing: Is it necessary? *Anaesthesia.* 2002;57:914-917.
24. Leurquin P, Van Casteren V, De Maeseneer J. Use of blood tests in general practice: A collaborative study in eight European countries. Eurosentinel study group. *Br J Gen Pract.* 1995;45:21-25.
25. Mills G, Chaffe A. Is cost-awareness really improving? *Health Trends.* 1993;25:38-40.
26. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. *Lancet.* 1999;354:1896-1900.
27. Munro J, Booth A, Nicholl J. Routine preoperative testing: A systematic review of the evidence. *Health Technol Assess.* 1997;1:i-iv, 1-62.
28. Organization for Economic Cooperation and Development. *Hospital services -% total expenditure on health, 2002. OECD health data 2006.* Paris: OECD; 2006.
29. Perrine TR. Physicians' knowledge of common outpatient medical costs in the Kanawha Valley-Charleston, West Virginia. *W V Med J.* 1982;78:90-97.
30. Prosser H, Walley T. A qualitative study of GP's and PCO stakeholders' views on the importance and influence of cost on prescribing. *Soc Sci Med.* 2005;60:1335-1346.
31. Ringenberg R. Cost awareness by family practice residents of commonly used laboratory tests, x-ray tests and medications. *Indiana Med.* 1988;81:136-141.
32. Sachdeva RC, Jefferson LS, Coss-Bu J, et al. Effects of availability of patient-related charges on practice patterns and cost containment in the pediatric intensive care unit. *Crit Care Med.* 1996;24:501-506.
33. Saunders AF, Divine GW, Weinberger M. Physicians' awareness of mammography charges. *Am J Prev Med.* 1994;10:357-360.
34. Schlunzen L, Simonsen MS, Spangenberg NLM, Carlsson P. Cost consciousness among anaesthetic staff. *Acta Anaesthesiol Scand.* 1999;43:202-205.
35. Shrank WH, Joseph GJ, Choudhry NK, et al. Physicians' perceptions of relevant prescription drug costs: Do costs the individual patient or to the population matter most? *Am J Manag Care.* 2006;12:545-551.
36. Skipper JK Jr, Smith G, Mulligan JL, Garg ML. Physicians' knowledge of cost: The case of diagnostic tests. *Inquiry.* 1976;13:194-198.
37. Smellie WS, Murphy MJ, Galloway PJ, et al. Audit of an emergency biochemistry service. *J Clin Pathol.* 1995;48:1126-1129.
38. Templeton L, Deehan A, Taylor C, Drummond C, Strang J. Surveying general practitioners: Does a low response rate matter? *Br J Gen Pract.* 1997;47:91-94.
39. Wynick D, Jessop JH. A survey of cost awareness among hospital medical staff. *Health Trends.* 1985;17:24.